Aims The association between atrial fibrillation (AF) and dementia is well documented, but it
is not clear if oral anticoagulant treatment offers protection. The aim of the study is therefore …

Importance Vitamin K antagonist (eg, warfarin) use is nowadays challenged by the non–
vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation …

Background: Patients with dementia might have higher risk for hemorrhagic complications
with anticoagulant therapy prescribed for atrial fibrillation (AF). Objective: This study …

Background Biologic prostheses are preferred for surgical aortic valve replacement (SAVR)
in patients more than 70 years of age in clinical practice. This study investigated differences …

Background Safety data for different anticoagulant medications in venous thromboembolism
(VTE) are scarce, in particular for extended treatment. Objectives To compare major …

Background For patients with atrial fibrillation, non-vitamin K oral anticoagulants, or NOACs
(dabigatran, rivaroxaban, edoxaban, and apixaban) have been proven non-inferior or …

â••Unreal worldâ•• or â••real worldâ•• data in oral anticoagulant treatment of atrial fibrillation
Page 1 © Schattauer 2016 Thrombosis and Haemostasis 116.4/2016 587 Invited Editorial Focus …

Aims Non-vitamin K antagonist oral anticoagulants (NOACs) were in pivotal randomised
controlled trials at least non-inferior to warfarin for stroke prevention in atrial fibrillation, but …

OBJECTIVES The optimal choice of valve prosthesis in surgical aortic valve replacement for
infective endocarditis (IE) is controversial. We studied outcomes after mechanical versus …

Objectives To compare effectiveness of warfarin and antiplatelet exposure regarding both
thrombotic and bleeding events, following surgical aortic valve replacement with a biological …